ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 1,679,860 shares, a drop of 0.9% from the October 13th total of 1,694,466 shares. Currently, 10.6% of the company’s shares are short sold. Based on an average daily volume of 2,347,634 shares, the short-interest ratio is presently 0.7 days.

Shares of ImmunoCellular Therapeutics (IMUC) opened at $0.32 on Friday. ImmunoCellular Therapeutics has a 12 month low of $0.25 and a 12 month high of $4.27.

Separately, Maxim Group reiterated a “hold” rating on shares of ImmunoCellular Therapeutics in a report on Thursday, August 24th.

ILLEGAL ACTIVITY WARNING: “ImmunoCellular Therapeutics Ltd (IMUC) Sees Significant Decrease in Short Interest” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/11/17/immunocellular-therapeutics-ltd-imuc-sees-significant-decrease-in-short-interest.html.

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.